Clinical Trial Update: Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating combination chemotherapy with or without bortezomib in relapsed or refractory mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: University Hospital Plymouth NHS Trust | Conditions: Lymphoma | Phase 2 | Status: COMPLETED